Skip to main content
SpringerLink
Log in

Intrahepatic cholangiocarcinoma: MRI texture signature as predictive biomarkers of immunophenotyping and survival

  • Hepatobiliary-Pancreas
  • Published:
European Radiology Aims and scope Submit manuscript

Abstract

Objective

Clinical evidence suggests that the response to immune checkpoint blockade depends on the immune status in the tumor microenvironment. This study aims to predict the immunophenotyping (IP) and overall survival (OS) of intrahepatic cholangiocarcinoma (ICC) patients using preoperative magnetic resonance imaging (MRI) texture analysis.

Methods

A total of 78 ICC patients were included and divided into inflamed (n = 26) or non-inflamed (n = 52) immunophenotyping based on the density of CD8+ T cells. The enhanced T1-weighted MRI in the arterial phase was employed with texture analysis. The logistic regression analysis was applied to select the significant features related to IP. The OS-related feature was determined by Cox proportional-hazards model and Kaplan-Meier analysis. IP and OS predictive models were developed using the selected features, respectively.

Results

Three wavelets and one 3D feature have favorable ability to discriminate IP, a combination of which performed best with an AUC of 0.919. The inflamed immunophenotyping had a better prognosis than the non-inflamed one. The 5-year survival rates of the two groups were 48.5% and 25.3%, respectively (p < 0.05). The only wavelet-HLH_firstorder_Median feature was associated with OS and used to build the OS predictive model with a C-index of 0.70 (95% CI, 0.57, 0.82), which could well stratify ICC patients into high- and low-risk groups. The 1-, 3-, and 5-year survival probabilities of the stratified groups were 62.5%, 30.0%, and 24.2%, and 89.5%, 62.2%, and 42.1%, respectively (p < 0.05).

Conclusion

The MRI texture signature could serve as a potential predictive biomarker for the IP and OS of ICC patients.

Key Points

• The MRI texture signature, including three wavelets and one 3D feature, showed significant associations with immunophenotyping of ICC, and all have favorable ability to discriminate immunophenotyping; a combination of the above features performed best with an AUC of 0.919.

• The only wavelet-HLH_firstorder_Median feature was associated with the OS of ICC and used to build the OS predictive model, which could well stratify ICC patients into high- and low-risk groups.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Abbreviations

AUC:

Area under the curve

GLCM:

Gray-level co-occurrence matrix

GLDM:

Gray-level dependence matrix

GLRLM:

Gray-level run length matrix

GLSZM:

Gray-level size zone matrix

ICB:

Immune checkpoint blockade

ICC:

Intrahepatic cholangiocarcinoma

IQR:

Interquartile range

MRI:

Magnetic resonance imaging

NGTDM:

Neighboring gray-tone difference matrix

OS:

Overall survival

PD-1:

Programmed cell death protein 1

PD-L1:

Programmed cell death protein ligand 1

ROC:

Receiver operating characteristic

ROI:

Regions of interest

TILs:

Tumor-infiltrating lymphocytes

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108

    Article  Google Scholar 

  2. Razumilava N, Gores GJ (2014) Cholangiocarcinoma. Lancet 383:2168–2179

    Article  Google Scholar 

  3. Bridgewater J, Galle PR, Khan SA et al (2014) Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 60:1268–1289

    Article  Google Scholar 

  4. Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM (2014) Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg 149:565–574

    Article  Google Scholar 

  5. de Jong MC, Nathan H, Sotiropoulos GC et al (2011) Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 29:3140–3145

    Article  Google Scholar 

  6. Smyth MJ, Ngiow SF, Ribas A, Teng MW (2016) Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol 13:143–158

    Article  CAS  Google Scholar 

  7. Schmid P, Adams S, Rugo HS et al (2018) Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379:2108–2121

    Article  CAS  Google Scholar 

  8. Migden MR, Rischin D, Schmults CD et al (2018) PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 379:341–351

    Article  CAS  Google Scholar 

  9. Le DT, Uram JN, Wang H et al (2015) PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520

    Article  CAS  Google Scholar 

  10. Kansy BA, Concha-Benavente F, Srivastava RM et al (2017) PD-1 Status in CD8(+) T cells associates with survival and anti-PD-1 therapeutic outcomes in head and neck cancer. Cancer Res 77:6353–6364

    Article  CAS  Google Scholar 

  11. Chowell D, Morris LGT, Grigg CM et al (2018) Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 359:582–587

    Article  CAS  Google Scholar 

  12. Ansell SM, Lesokhin AM, Borrello I et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372:311–319

    Article  Google Scholar 

  13. Sabbatino F, Villani V, Yearley JH et al (2016) PD-L1 and HLA class I antigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma. Clin Cancer Res 22:470–478

    Article  CAS  Google Scholar 

  14. Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer-immune set point. Nature 541:321–330

    Article  CAS  Google Scholar 

  15. Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454

    Article  CAS  Google Scholar 

  16. Herbst RS, Soria JC, Kowanetz M et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563–567

    Article  CAS  Google Scholar 

  17. Hamid O, Robert C, Daud A et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134–144

    Article  CAS  Google Scholar 

  18. Kim JM, Chen DS (2016) Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol 27:1492–1504

    Article  CAS  Google Scholar 

  19. Hugo W, Zaretsky JM, Sun L et al (2016) Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165:35–44

    Article  CAS  Google Scholar 

  20. Sharma P, Allison JP (2015) The future ofimmune checkpoint therapy. Science 348(6230):56–61

    Article  CAS  Google Scholar 

  21. Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028

    Article  Google Scholar 

  22. Tumeh PC, Harview CL, Yearley JH et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568–571

    Article  CAS  Google Scholar 

  23. Shields AF, Jacobs PM, Sznol M et al (2018) Immune modulation therapy and imaging: workshop report. J Nucl Med 59:410–417

    Article  CAS  Google Scholar 

  24. Ku YJ, Kim HH, Cha JH et al (2016) Correlation between MRI and the level of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer. AJR Am J Roentgenol 207:1146–1151

    Article  Google Scholar 

  25. Ku YJ, Kim HH, Cha JH et al (2018) Predicting the level of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: usefulness of breast MRI computer-aided detection and diagnosis. J Magn Reson Imaging 47:760–766

    Article  Google Scholar 

  26. Lambin P, Leijenaar RTH, Deist TM et al (2017) Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 14:749–762

    Article  Google Scholar 

  27. Sun R, Limkin EJ, Vakalopoulou M et al (2018) A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol 19:1180–1191

    Article  CAS  Google Scholar 

  28. Hegde PS, Karanikas V, Evers S (2016) The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res 22:1865–1874

    Article  CAS  Google Scholar 

  29. Zhang J, Huang Z, Cao L et al (2020) Differentiation combined hepatocellular and cholangiocarcinoma from intrahepatic cholangiocarcinoma based on radiomics machine learning. Ann Transl Med 8:119

    Article  Google Scholar 

  30. Xu L, Yang P, Liang W et al (2019) A radiomics approach based on support vector machine using MR images for preoperative lymph node status evaluation in intrahepatic cholangiocarcinoma. Theranostics 9:5374–5385

    Article  Google Scholar 

  31. Liang W, Yang P, Huang R et al (2019) A combined nomogram model to preoperatively predict histologic grade in pancreatic neuroendocrine tumors. Clin Cancer Res 25:584–594

    Article  Google Scholar 

  32. Wu W, Parmar C, Grossmann P et al (2016) Exploratory study to identify radiomics classifiers for lung cancer histology. Front Oncol 6:71

    PubMed  PubMed Central  Google Scholar 

  33. Ahmed AA, Elmohr MM, Fuentes D et al (2020) Radiomic mapping model for prediction of Ki-67 expression in adrenocortical carcinoma. Clin Radiol 75:479 e417–479 e422

    Article  Google Scholar 

  34. Tixier F, Le Rest CC, Hatt M et al (2011) Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med 52:369–378

    Article  Google Scholar 

  35. Asahi Y, Hatanaka KC, Hatanaka Y et al (2020) Prognostic impact of CD8+ T cell distribution and its association with the HLA class I expression in intrahepatic cholangiocarcinoma. Surg Today. https://doi.org/10.1007/s00595-020-01967-y

  36. Gu FM, Gao Q, Shi GM et al (2012) Intratumoral IL-17(+) cells and neutrophils show strong prognostic significance in intrahepatic cholangiocarcinoma. Ann Surg Oncol 19:2506–2514

    Article  Google Scholar 

  37. Liang W, Xu L, Yang P et al (2018) Novel nomogram for preoperative prediction of early recurrence in intrahepatic cholangiocarcinoma. Front Oncol 8:360

    Article  Google Scholar 

  38. Ji GW, Zhu FP, Zhang YD et al (2019) A radiomics approach to predict lymph node metastasis and clinical outcome of intrahepatic cholangiocarcinoma. Eur Radiol 29:3725–3735

    Article  Google Scholar 

  39. Mosconi C, Cucchetti A, Bruno A et al (2020) Radiomics of cholangiocarcinoma on pretreatment CT can identify patients who would best respond to radioembolisation. Eur Radiol. https://doi.org/10.1007/s00330-020-06795-9

Download references

Funding

This project was supported by the National Natural Science Foundations of China (81771797, 81971571) and the 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University, China (ZYJC18008).

Author information

Author notes

  1. Jun Zhang and Zhenru Wu contributed equally to this work.

Authors and Affiliations

  1. Department of Radiology, West China Hospital, Sichuan University, Chengdu, 610041, China

    Jun Zhang, Jian Zhao, Fang Yuan & Bin Song

  2. Laboratory of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China

    Zhenru Wu & Yujun Shi

  3. Pharmaceutical Diagnostic Team, GE Healthcare, Life Sciences, Beijing, 100176, China

    Siyun Liu & Xin Zhang

Authors
  1. Jun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhenru Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jian Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Siyun Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fang Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yujun Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bin Song
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yujun Shi or Bin Song.

Ethics declarations

Guarantor

The scientific guarantor of this publication is Dr. Bin Song.

Conflict of interest

The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.

Statistics and biometry

No complex statistical methods were necessary for this paper.

Informed consent

Written informed consent was waived by the Institutional Review Board.

Ethical approval

Institutional Review Board approval was obtained.

Methodology

• retrospective

• diagnostic or prognostic study

• performed at one institution

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

ESM 1

(DOCX 2615 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, J., Wu, Z., Zhao, J. et al. Intrahepatic cholangiocarcinoma: MRI texture signature as predictive biomarkers of immunophenotyping and survival. Eur Radiol 31, 3661–3672 (2021). https://doi.org/10.1007/s00330-020-07524-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00330-020-07524-y

Keywords

Search

Navigation